Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezabenlimab Alone or with BI 836880 in Anal Canal SCCA
NCT04499352Phase 2Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2020
- Primary completion
- Oct 2020
- Modality
- Bispecific Antibodies, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ezabenlimab, BI 836880 in anal canal squamous cell carcinoma (SCCA), sponsored by Boehringer Ingelheim. Planned start Sep 2020; status: withdrawn.
02
Drugs
ezabenlimabBI 836880
03
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT04499352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04499352.